Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
(Thomson Reuters ONE) -
COPENHAGEN, Denmark, June 15, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
announced today that the Public Health Agency of Canada (PHAC) has exercised an
option for the supply of 171,000 doses of IMVAMUNE(®) smallpox vaccine to the
national stockpile at a total value of USD 7.7 million.
This option builds upon an initial order of 189,000 doses, comprising a total of
360,000 doses ordered by PHAC, to date. Deliveries from the initial order are
taking place throughout 2016, and the new order will be delivered in 2017 and
2018. The Company also has an ongoing contract with the Canadian Department of
National Defence (DND), under which additional options for IMVAMUNE remain
exercisable. Approved in Canada in 2013, IMVAMUNE is a non-replicating smallpox
vaccine, which is being stockpiled for use in both the general population as
well as individuals who are contraindicated to traditional smallpox vaccines,
such as HIV-infected and people suffering from skin disorders.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "We
are pleased to continue our collaboration with the Canadian government in their
efforts to secure protection for its citizens. This collaboration dates back to
2008 when we started deliveries to the Canadian Department of National Defence,
and was since broadened to include the Public Health Agency of Canada, who also
recognized the need for establishing a smallpox vaccine stockpile for the
general population. We look forward to continuing and expanding our partnership
engagement on various bio preparedness matters, including smallpox."
The contents of this announcement do not affect the Company's expectations for
the financial results for 2016.
About IMVAMUNE Smallpox Vaccine
IMVAMUNE is being developed as a smallpox vaccine for individuals for whom
traditional replicating vaccines are contraindicated, such as people with atopic
dermatitis (AD) and HIV. IMVAMUNE is the Company's most advanced commercial
program. Studies comprising more than 7,600 subjects, including people diagnosed
with AD or infected with HIV, demonstrate that IMVAMUNE has a favorable safety
profile. In 2013, the vaccine was approved in Canada under the trade name
IMVAMUNE and in the European Union under the trade name IMVANEX(®).
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, which has been fast-tracked, with the
backing of worldwide health authorities, and a vaccine for the prevention and
treatment of HPV. Additionally, in collaboration with the National Cancer
Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies, including PROSTVAC(®), which is currently in Phase 3 clinical
development for the treatment of advanced prostate cancer. The company has
partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control, that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. All such forward-looking
statements are expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. We
undertake no obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made, except as
required by law.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Company Announcement no. 21 / 2016
2016-21-en:
http://hugin.info/100065/R/2020917/750723.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#2020917]
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2016 - 15:04 Uhr
Sprache: Deutsch
News-ID 477899
Anzahl Zeichen: 5757
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 332 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
